3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors

  • Bioorg Med Chem Lett. 2006 Jul 15;16(14):3789-92. doi: 10.1016/j.bmcl.2006.04.043.
Christopher M McBride  1 ,  Paul A Renhowe ,  Thomas G Gesner ,  Johanna M Jansen ,  Julie Lin ,  Sylvia Ma ,  Yasheen Zhou ,  Cynthia M Shafer
Affiliations
  • 1. Small Molecule Drug Discovery, Medicinal Chemistry Department, Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA.
PMID: 16678414 DOI: 10.1016/j.bmcl.2006.04.043
Abstract

The 3-benzimidazol-2-yl-1H-indazole scaffold was developed as an alternate scaffold for our receptor tyrosine kinase (RTK) inhibitor program. In exploring the SAR of this series, it was discovered that a subset of these compounds potently inhibit the enzyme c-ABL. The SAR of these compounds is described.